Tags · Status
needs a source
A claim in this topic has been challenged and not yet supported.
Related in this group: solved · open question · long read · beginner friendly · worked example · data table · disputed
90 topics · page 2 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
|
Grapefruit: why this class is not the class that cares
Grapefruit: why this class is not the class that cares Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about grapefruit in a thread last spring and I would like…
|
+126 | 139 | 4k | 4mo |
|
Preprint servers and what screening they do — the long version
On the subject in the title: Preprint servers and what screening they do — the long version Working notes rather than a conclusion. A preprint question rather than a question about the finding in it. The…
|
+7 | 11 | 26k | 4mo |
|
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The manuscript is on a…
|
+95 | 106 | 5.6k | 4mo |
|
Follow-up: Levothyroxine timing: a real interaction with a simple fix
On the subject in the title: Levothyroxine timing: a real interaction with a simple fix Working notes rather than a conclusion. A follow-up question about Levothyroxine timing that I did not know to ask the…
|
+2 | 6 | 8.1k | 4mo |
|
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. IGF-1, and specifically the version of it that the documentation does not…
|
+5 | 9 | 35k | 4mo |
|
Reading an interaction checker output critically
On the subject in the title: Reading an interaction checker output critically Working notes rather than a conclusion. A question about reading an interaction checker output that I think has a definite answer,…
|
+144 | 152 | 3k | 4mo |
|
Warfarin and altered intake: the monitoring argument
Warfarin and altered intake: the monitoring argument — setting out what I have, and where I think it stops being reliable. Proposing that warfarin and altered intake deserves a maintained page rather than a…
|
2 | 11k | 4mo | |
|
Warfarin and altered intake: the monitoring argument — the long version
Posting this under the heading it deserves: Warfarin and altered intake: the monitoring argument — the long version Everything below is what sits behind that. A narrow question about Warfarin and altered…
|
+123 | 134 | 40k | 4mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin oral versus injected administration claims…
|
+20 | 24 | 47k | 4mo |
|
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. A preprint question rather than a question about the finding in it.…
|
2 | 467 | 4mo | |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…
|
+35 | 39 | 688 | 5mo |
|
Alcohol: what is documented and what is folklore — the long version
Alcohol: what is documented and what is folklore — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about Alcohol, deliberately narrow, because the…
|
+9 | 13 | 7.3k | 6mo |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Reading back through what has been written here about AOD-9604, three…
|
+40 | 44 | 2.8k | 6mo |
|
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+8 | 12 | 51k | 7mo |
|
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Reading an unrefereed manuscript properly, and asking whether I am doing it…
|
2 | 48k | 7mo | |
|
Tracking a preprint to publication: a worked example
Tracking a preprint to publication: a worked example Writing it up because I had to work it out twice and would rather nobody else did. A preprint question rather than a question about the finding in it. The…
|
+133 | 147 | 15k | 7mo |
|
A preprint whose numbers changed substantially at publication — what changed since
On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. A preprint question rather than a question about the…
|
+3 | 7 | 125 | 8mo |
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…
|
+100 | 108 | 1.3k | 8mo |
|
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+86 | 97 | 62k | 8mo |
|
Conference abstracts as evidence: the weakest common citation
On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Reading an unrefereed manuscript properly, and asking whether I am doing it…
|
+1 | 5 | 2k | 9mo |
|
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…
|
2 | 309 | 9mo | |
|
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The…
|
+90 | 95 | 21k | 9mo |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
|
+81 | 87 | 35k | 10mo |
|
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…
|
+62 | 66 | 26k | 10mo |
|
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold?
The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. A question about…
|
+103 | 115 | 24k | 10mo |
|
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…
|
+50 | 54 | 32k | 10mo |
|
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I would like to know what people here actually do about BPC-157,…
|
+44 | 48 | 3k | 10mo |
|
Analytical identity of BPC-157: a 15-mer with a simple mass
Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Something about analytical identity of BPC-157 does not reconcile…
|
+3 | 7 | 5.2k | 10mo |
|
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. A comparison question rather than a question about one compound.…
|
+120 | 129 | 61k | 11mo |